Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $163 from $175 and keeps an Equal Weight rating on the shares ...
FiercePharma2d
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
pharmaphorum3d
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
The Pharma Letter3d
EC approves added use for J&J’s Lazcluze combo with Rybrevant for lung cancer
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
PharmaTimes3d
EC approves lazertinib in combination with amivantamab for NSCLC patients
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...
manilatimes4d
Prince Harry's battle against Murdoch UK tabloids goes to trial
Prince Harry's hotly anticipated lawsuit trial against a British tabloid publisher alleging it carried out unlawful ...
Healio14d
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
BioWorld15d
Yuhan, Oscotec stock gains as J&J hits ‘gold standard’ in NSCLC
Yuhan Corp., Oscotec Inc. and Genosco Inc. were three companies with Asian ties to reap benefit from Johnson & Johnson’s stellar top-line Mariposa study results, wherein J&J’s Rybrevant ...